Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Policlinico S.Orsola-Malpighi
Bolonia, ItaliaPublikationen in Zusammenarbeit mit Forschern von Policlinico S.Orsola-Malpighi (87)
2024
-
An artificial intelligence-assisted system versus white light endoscopy alone for adenoma detection in individuals with Lynch syndrome (TIMELY): an international, multicentre, randomised controlled trial
The Lancet Gastroenterology and Hepatology, Vol. 9, Núm. 9, pp. 802-810
-
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma
Haematologica
-
Corrigendum to “European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO” [Eur J Surg Oncol 50 (1) (January 2024) 107292] (European Journal of Surgical Oncology (2024) 50(1), (S0748798323009307), (10.1016/j.ejso.2023.107292))
European Journal of Surgical Oncology
-
EUSOMA quality indicators for non-metastatic breast cancer: An update
European Journal of Cancer, Vol. 198
-
European guidelines for the diagnosis, treatment and follow-up of breast lesions with uncertain malignant potential (B3 lesions) developed jointly by EUSOMA, EUSOBI, ESP (BWG) and ESSO
European Journal of Surgical Oncology, Vol. 50, Núm. 1
-
Factors Impacting Survival After Transarterial Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Combined Analysis of the Prospective CIRT Studies
CardioVascular and Interventional Radiology, Vol. 47, Núm. 3, pp. 310-324
-
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial
The Lancet Haematology, Vol. 11, Núm. 3, pp. e216-e227
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis
Haematologica, Vol. 109, Núm. 7, pp. 2239-2249
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation: The PURPOSE Study
JACC: Cardiovascular Interventions, Vol. 17, Núm. 13, pp. 1597-1606
-
Performance of balloon-expandable transcatheter bioprostheses in inoperable patients with pure aortic regurgitation of a native valve: The BE-PANTHEON international project
Cardiovascular Revascularization Medicine
-
Plain language summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma
Future Oncology, Vol. 20, Núm. 18, pp. 1221-1235
-
Recurrence and tumor-related death after resection of hepatocellular carcinoma in patients with metabolic syndrome
JHEP Reports, Vol. 6, Núm. 7
-
Robotic Versus Laparoscopic Liver Resection in Various Settings: An International Multicenter Propensity Score Matched Study of 10.075 Patients
Annals of Surgery, Vol. 280, Núm. 1, pp. 108-117
-
Treatment and outcomes in breast cancer patients: A cross section study from the EUSOMA breast centre network
European Journal of Cancer, Vol. 196
-
Trends in the characteristics and perioperative outcomes of patients undergoing laparoscopic and open resections for benign liver lesions: An international multicenter retrospective cohort study of 845 patients
HPB, Vol. 26, Núm. 2, pp. 188-202
2023
-
Alternative forms of portal vein revascularization in liver transplant recipients with complex portal vein thrombosis
Journal of Hepatology, Vol. 78, Núm. 4, pp. 794-804
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia